Newborn screening samples are used to test more than 4 million infants each year for life-threatening diseases that are treatable if found at birth. These specimens also represent a potentially invaluable resource for public health and biomedical research. The IOM held a workshop to examine issues surrounding the use of residual specimens for translational research.
1 Front Matter; 2 1 Introduction; 3 2 Newborn Screening as a Public Health Program; 4 3 Uses of Residual Newborn Screening Samples in Research; 5 4 Concerns About the Use of Residual Newborn Screening Samples; 6 5 Review and Consent in the Use of Residual Newborn Screening Samples; 7 6 Parental and Public Education; 8 7 Workshop Overview and Wrap-Up; 9 References; 10 Appendix A: Workshop Agenda; 11 Appendix B: Speaker Biographical Sketches
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Center for Medical Technology Policy, Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Steve Olson, Adam C. Berger
Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Steve Olson, Sarah H. Beachy, Samuel G. Johnson, Adam C. Berger
Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Adam C. Berger, Steve Olson, Samuel G. Johnson, Sarah H. Beachy
Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Adam C. Berger, Steve Olson, Samuel G. Johnson, Sarah H. Beachy
Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Adam C. Berger, Steve Olson, Samuel G. Johnson, Sarah H. Beachy
Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Steve Olson, Adam C. Berger, Sarah H. Beachy
Institute of Medicine, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, Adam C. Berger, Steve Olson, Samuel G. Johnson, Sarah H. Beachy